William E Evans

List of Publications by Year
in descending order

471 papers	55,163 citations	906 116 h-index	1347 223 g-index
487 all docs	487 docs citations	487 times ranked	31759 citing authors

#	Article	IF	Citations
1	Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics. Science, 1999, 286, 487-491.	12.6	2,291
2	Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell, 2002, 1, 133-143.	16.8	1,756
3	Treatment of Acute Lymphoblastic Leukemia. New England Journal of Medicine, 2006, 354, 166-178.	27.0	1,740
4	Pharmacogenomics â€" Drug Disposition, Drug Targets, and Side Effects. New England Journal of Medicine, 2003, 348, 538-549.	27.0	1,609
5	Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature, 2007, 446, 758-764.	27.8	1,602
6	The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature, 2012, 481, 157-163.	27.8	1,430
7	Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia. New England Journal of Medicine, 2014, 371, 1005-1015.	27.0	1,161
8	Treating Childhood Acute Lymphoblastic Leukemia without Cranial Irradiation. New England Journal of Medicine, 2009, 360, 2730-2741.	27.0	1,059
9	A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncology, The, 2009, 10, 125-134.	10.7	826
10	Acute Lymphoblastic Leukemia. New England Journal of Medicine, 1998, 339, 605-615.	27.0	809
11	Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration. Journal of Clinical Oncology, 2015, 33, 2938-2948.	1.6	747
12	Moving towards individualized medicine with pharmacogenomics. Nature, 2004, 429, 464-468.	27.8	702
13	Acute Myeloid Leukemia in Children Treated with Epipodophyllotoxins for Acute Lymphoblastic Leukemia. New England Journal of Medicine, 1991, 325, 1682-1687.	27.0	697
14	Mercaptopurine Therapy Intolerance and Heterozygosity at the Thiopurine S-Methyltransferase Gene Locus. Journal of the National Cancer Institute, 1999, 91, 2001-2008.	6.3	680
15	Molecular Diagnosis of Thiopurine S-Methyltransferase Deficiency: Genetic Basis for Azathioprine and Mercaptopurine Intolerance. Annals of Internal Medicine, 1997, 126, 608.	3.9	679
16	Pharmacogenomics in the clinic. Nature, 2015, 526, 343-350.	27.8	642
17	Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia. Cancer Cell, 2012, 22, 153-166.	16.8	621
18	Pharmacogenomics and Individualized Drug Therapy. Annual Review of Medicine, 2006, 57, 119-137.	12.2	576

#	Article	IF	Citations
19	Gene-Expression Patterns in Drug-Resistant Acute Lymphoblastic Leukemia Cells and Response to Treatment. New England Journal of Medicine, 2004, 351, 533-542.	27.0	565
20	Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing. Clinical Pharmacology and Therapeutics, 2011, 89, 387-391.	4.7	504
21	Germline genomic variants associated with childhood acute lymphoblastic leukemia. Nature Genetics, 2009, 41, 1001-1005.	21.4	459
22	Preemptive Clinical Pharmacogenetics Implementation: Current Programs in Five US Medical Centers. Annual Review of Pharmacology and Toxicology, 2015, 55, 89-106.	9.4	442
23	Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?. Blood, 2012, 120, 1165-1174.	1.4	439
24	Conventional Compared with Individualized Chemotherapy for Childhood Acute Lymphoblastic Leukemia. New England Journal of Medicine, 1998, 338, 499-505.	27.0	438
25	Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on <scp>TPMT</scp> and <scp>NUDT</scp>15 Genotypes: 2018 Update. Clinical Pharmacology and Therapeutics, 2019, 105, 1095-1105.	4.7	428
26	Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia, 2000, 14, 567-572.	7.2	422
27	Extended Follow-up of Long-Term Survivors of Childhood Acute Lymphoblastic Leukemia. New England Journal of Medicine, 2003, 349, 640-649.	27.0	415
28	Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood, 2004, 104, 2690-2696.	1.4	412
29	Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. Journal of Pediatrics, 1991, 119, 985-989.	1.8	402
30	Preponderance of Thiopurine S-Methyltransferase Deficiency and Heterozygosity Among Patients Intolerant to Mercaptopurine or Azathioprine. Journal of Clinical Oncology, 2001, 19, 2293-2301.	1.6	400
31	High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet, The, 1999, 354, 34-39.	13.7	390
32	NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity. Nature Genetics, 2016, 48, 367-373.	21.4	389
33	PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. Nature Genetics, 2019, 51, 296-307.	21.4	384
34	Clinical Pharmacodynamics of High-Dose Methotrexate in Acute Lymphocytic Leukemia. New England Journal of Medicine, 1986, 314, 471-477.	27.0	369
35	Inherited NUDT15 Variant Is a Genetic Determinant of Mercaptopurine Intolerance in Children With Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2015, 33, 1235-1242.	1.6	369
36	Pharmacogenomics: The Inherited Basis for Interindividual Differences in Drug Response. Annual Review of Genomics and Human Genetics, 2001, 2, 9-39.	6.2	365

#	Article	IF	Citations
37	Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy. Lancet, The, 1991, 337, 61-66.	13.7	351
38	Prognostic Importance of 6-Mercaptopurine Dose Intensity in Acute Lymphoblastic Leukemia. Blood, 1999, 93, 2817-2823.	1.4	348
39	Multiplex assessment of protein variant abundance by massively parallel sequencing. Nature Genetics, 2018, 50, 874-882.	21.4	323
40	A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 949-953.	7.1	316
41	The Pediatric Cancer Genome Project. Nature Genetics, 2012, 44, 619-622.	21.4	315
42	Germline Genetic Variation in an Organic Anion Transporter Polypeptide Associated With Methotrexate Pharmacokinetics and Clinical Effects. Journal of Clinical Oncology, 2009, 27, 5972-5978.	1.6	305
43	Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing: 2013 Update. Clinical Pharmacology and Therapeutics, 2013, 93, 324-325.	4.7	304
44	PHARMACOGENOMICS: Unlocking the Human Genome for Better Drug Therapy. Annual Review of Pharmacology and Toxicology, 2001, 41, 101-121.	9.4	302
45	Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2* activities. Clinical Pharmacology and Therapeutics, 1992, 52, 643-658.	4.7	295
46	Higher Frequency of Glutathione S-Transferase Deletions in Black Children With Acute Lymphoblastic Leukemia. Blood, 1997, 89, 1701-1707.	1.4	283
47	Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinases. Science, 1995, 267, 886-891.	12.6	276
48	Methotrexate-Induced Neurotoxicity and Leukoencephalopathy in Childhood Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2014, 32, 949-959.	1.6	275
49	A 50-Year Journey to Cure Childhood Acute Lymphoblastic Leukemia. Seminars in Hematology, 2013, 50, 185-196.	3.4	264
50	Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia. Nature Genetics, 2013, 45, 290-294.	21.4	264
51	Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse. Nature Genetics, 2013, 45, 1494-1498.	21.4	264
52	Enhanced proteolysis of thiopurine S -methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT â^— 3 A , TPMT â^— 2): Mechanisms for the genetic polymorphism of TPMTâ€‰activity. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 6444-6449.	7.1	262
53	Cumulative Incidence of Secondary Neoplasms as a First Event After Childhood Acute Lymphoblastic Leukemia. JAMA - Journal of the American Medical Association, 2007, 297, 1207.	7.4	261
54	Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms. Pharmacogenetics and Genomics, 1996, 6, 279-290.	5.7	253

#	Article	IF	Citations
55	Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia, 2010, 24, 371-382.	7.2	248
56	Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Blood, 2013, 122, 2622-2629.	1.4	248
57	Thiopurine methyltransferase activity in American white subjects and black subjects. Clinical Pharmacology and Therapeutics, 1994, 55, 15-20.	4.7	242
58	Polymorphism of the thiopurine S-methyltransferase gene in African- Americans. Human Molecular Genetics, 1999, 8, 371-376.	2.9	239
59	Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells. Nature Genetics, 2003, 34, 85-90.	21.4	239
60	Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nature Genetics, 2011, 43, 237-241.	21.4	239
61	Childhood acute lymphoblastic leukaemia â€“ current status and future perspectives. Lancet Oncology, The, 2001, 2, 597-607.	10.7	237
62	Association of an Inherited Genetic Variant With Vincristine-Related Peripheral Neuropathy in Children With Acute Lymphoblastic Leukemia. JAMA - Journal of the American Medical Association, 2015, 313, 815.	7.4	234
63	Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. Genome Research, 2012, 22, 1-8.	5.5	232
64	Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. Nature Genetics, 2016, 48, 1481-1489.	21.4	231
65	Outcomes of Children With BCR-ABL1â€“Like Acute Lymphoblastic Leukemia Treated With Risk-Directed Therapy Based on the Levels of Minimal Residual Disease. Journal of Clinical Oncology, 2014, 32, 3012-3020.	1.6	223
66	PG4KDS: A model for the clinical implementation of preâ€emptive pharmacogenetics. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2014, 166, 45-55.	1.6	221
67	Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood, 2011, 117, 2340-2347.	1.4	219
68	Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements. Leukemia, 2003, 17, 700-706.	7.2	216
69	Late Effects of Treatment in Survivors of Childhood Acute Myeloid Leukemia. Journal of Clinical Oncology, 2000, 18, 3273-3279.	1.6	213
70	Novel Susceptibility Variants at 10p12.31-12.2 for Childhood Acute Lymphoblastic Leukemia in Ethnically Diverse Populations. Journal of the National Cancer Institute, 2013, 105, 733-742.	6.3	208
71	Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood, 2005, 105, 4752-4758.	1.4	205
72	Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy. Nature Reviews Cancer, 2006, 6, 117-129.	28.4	205

#	Article	IF	Citations
73	TEL gene rearrangement in acute lymphoblastic leukemia: a new genetic marker with prognostic significance.. Journal of Clinical Oncology, 1997, 15, 1150-1157.	1.6	198
74	Genetic Polymorphism of Inosine Triphosphate Pyrophosphatase Is a Determinant of Mercaptopurine Metabolism and Toxicity During Treatment for Acute Lymphoblastic Leukemia. Clinical Pharmacology and Therapeutics, 2009, 85, 164-172.	4.7	196
75	Genome-wide Interrogation of Germline Genetic Variation Associated With Treatment Response in Childhood Acute Lymphoblastic Leukemia. JAMA - Journal of the American Medical Association, 2009, 301, 393.	7.4	193
76	Patient characteristics associated with high-risk methotrexate concentrations and toxicity.. Journal of Clinical Oncology, 1994, 12, 1667-1672.	1.6	191
77	Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood, 2007, 109, 4151-4157.	1.4	190
78	Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. Blood, 2009, 113, 2014-2021.	1.4	189
79	Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital. Leukemia, 2000, 14, 2286-2294.	7.2	187
80	Development and use of active clinical decision support for preemptive pharmacogenomics. Journal of the American Medical Informatics Association: JAMIA, 2014, 21, e93-e99.	4.4	186
81	Early Intensification of Intrathecal Chemotherapy Virtually Eliminates Central Nervous System Relapse in Children With Acute Lymphoblastic Leukemia. Blood, 1998, 92, 411-415.	1.4	183
82	Pharmacogenetics of Thiopurine S-Methyltransferase and Thiopurine Therapy. Therapeutic Drug Monitoring, 2004, 26, 186-191.	2.0	183
83	Pharmacogenomics and Individualized Medicine: Translating Science Into Practice. Clinical Pharmacology and Therapeutics, 2012, 92, 467-75.	4.7	183
84	Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia. Lancet, The, 2000, 356, 285-290.	13.7	181
85	Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia.. Journal of Clinical Investigation, 1994, 94, 1996-2001.	8.2	180
86	Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia. Blood, 2000, 96, 3381-3384.	1.4	180
87	Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia. Leukemia, 1998, 12, 346-352.	7.2	179
88	Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia. Blood, 2008, 112, 4178-4183.	1.4	179
89	Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study. Lancet Oncology, The, 2015, 16, 465-474.	10.7	177
90	Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate.. Journal of Clinical Investigation, 1996, 97, 73-80.	8.2	177

#	Article	IF	Citations
91	Genome-wide study of methotrexate clearance replicates SLCO1B1. Blood, 2013, 121, 898-904.	1.4	174
92	Improved CNS Control of Childhood Acute Lymphoblastic Leukemia Without Cranial Irradiation: St Jude Total Therapy Study 16. Journal of Clinical Oncology, 2019, 37, 3377-3391.	1.6	169
93	ARID5B Genetic Polymorphisms Contribute to Racial Disparities in the Incidence and Treatment Outcome of Childhood Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2012, 30, 751-757.	1.6	165
94	The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Overcoming Challenges of Real-World Implementation. Clinical Pharmacology and Therapeutics, 2013, 94, 207-210.	4.7	164
95	6MP adherence in a multiracial cohort of children with acute lymphoblastic leukemia: a Children's Oncology Group study. Blood, 2014, 124, 2345-2353.	1.4	164
96	Germline genetic variation in ETV6 and risk of childhood acute lymphoblastic leukaemia: a systematic genetic study. Lancet Oncology, The, 2015, 16, 1659-1666.	10.7	161
97	Human Granulocyte Colony-Stimulating Factor after Induction Chemotherapy in Children with Acute Lymphoblastic Leukemia. New England Journal of Medicine, 1997, 336, 1781-1787.	27.0	158
98	Hypersensitivity or Development of Antibodies to Asparaginase Does Not Impact Treatment Outcome of Childhood Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2000, 18, 1525-1532.	1.6	155
99	Results of Therapy for Acute Lymphoblastic Leukemia in Black and White Children. JAMA - Journal of the American Medical Association, 2003, 290, 2001.	7.4	155
100	Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies. Leukemia, 1997, 11, 1813-1816.	7.2	154
101	Genetic Polymorphism of Thiopurine S-Methyltransferase: Molecular Mechanisms and Clinical Importance. Pharmacology, 2000, 61, 136-146.	2.2	152
102	Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia. Cancer Cell, 2005, 7, 375-386.	16.8	150
103	The Genomic Landscape of Childhood and Adolescent Melanoma. Journal of Investigative Dermatology, 2015, 135, 816-823.	0.7	148
104	Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. Blood, 2003, 101, 3862-3867.	1.4	145
105	Germline Genetic IKZF1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia. Cancer Cell, 2018, 33, 937-948.e8.	16.8	142
106	Ligation of CD38 suppresses human B lymphopoiesis.. Journal of Experimental Medicine, 1995, 181, 1101-1110.	8.5	140
107	Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy. Leukemia, 2017, 31, 333-339.	7.2	140
108	Pharmacogenetics of Cancer Therapy: Getting Personal. American Journal of Human Genetics, 1998, 63, 11-16.	6.2	134

#	Article	IF	Citations
109	Somatic deletions of genes regulating MSH2 protein stability cause DNA mismatch repair deficiency and drug resistance in human leukemia cells. Nature Medicine, 2011, 17, 1298-1303.	30.7	133
110	Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. Journal of Clinical Investigation, 2005, 115, 110-117.	8.2	129
111	Sex Differences in Prognosis for Children With Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 1999, 17, 818-818.	1.6	128
112	Drug methylation in cancer therapy: lessons from the TPMT polymorphism. Oncogene, 2003, 22, 7403-7413.	5.9	128
113	Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)/TCF3-PBX1. Leukemia, 2009, 23, 1406-1409.	7.2	128
114	Thiopurine methyltransferase in acute lymphoblastic leukemia. Blood, 2006, 107, 843-844.	1.4	127
115	The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia. Blood, 2006, 107, 769-776.	1.4	126
116	NALP3 inflammasome upregulation and CASP1 cleavage of the glucocorticoid receptor cause glucocorticoid resistance in leukemia cells. Nature Genetics, 2015, 47, 607-614.	21.4	126
117	Comparative cytotoxicity of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia.. Journal of Clinical Oncology, 1996, 14, 2370-2376.	1.6	125
118	Transporter-Mediated Protection against Thiopurine-Induced Hematopoietic Toxicity. Cancer Research, 2008, 68, 4983-4989.	0.9	124
119	Improved Prognosis for Older Adolescents With Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2011, 29, 386-391.	1.6	122
120	TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children. Journal of Clinical Oncology, 2018, 36, 591-599.	1.6	121
121	PharmGKB summary. Pharmacogenetics and Genomics, 2011, 21, 679-686.	1.5	120
122	Pharmacokinetics of vincristine in children and adolescents with acute lymphocytic leukemia. Journal of Pediatrics, 1994, 125, 642-649.	1.8	119
123	Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a phase I trial.. Journal of Clinical Oncology, 1987, 5, 1007-1014.	1.6	117
124	Systemic Exposure to Thiopurines and Risk of Relapse in Children With Acute Lymphoblastic Leukemia. JAMA Oncology, 2015, 1, 287.	7.1	114
125	Pharmacogenetics as a molecular basis for individualized drug therapy: the thiopurine S-methyltransferase paradigm. , 1999, 16, 342-349.		113
126	Clinical Pharmacokinetics-Pharmacodynamicsof Anticancer Drugs. Clinical Pharmacokinetics, 1989, 16, 327-336.	3.5	112

#	Article	IF	Citations
127	ETV6-RUNX1-positive childhood acute lymphoblastic leukemia: improved outcome with contemporary therapy. Leukemia, 2012, 26, 265-270.	7.2	112
128	A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. Blood, 2015, 125, 680-686.	1.4	110
129	Clinical evaluation of sequentially scheduled cisplatin and vm26 in neuroblastoma: Response and toxicity. Cancer, 1981, 48, 1715-1718.	4.1	107
130	Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects. Clinical Pharmacology and Therapeutics, 1991, 50, 308-313.	4.7	105
131	Reduced Folate Carrier Expression in Acute Lymphoblastic Leukemia: A Mechanism for Ploidy but not Lineage Differences in Methotrexate Accumulation. Blood, 1999, 93, 1643-1650.	1.4	105
132	Treatment Outcomes in Black and White Children With Cancer: Results From the SEER Database and St Jude Children's Research Hospital, 1992 Through 2007. Journal of Clinical Oncology, 2012, 30, 2005-2012.	1.6	104
133	Nomenclature for alleles of the thiopurine methyltransferase gene. Pharmacogenetics and Genomics, 2013, 23, 242-248.	1.5	104
134	Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia. Blood, 2012, 120, 4197-4204.	1.4	103
135	Pharmacokinetic monitoring of high-dose methotrexate. Cancer Chemotherapy and Pharmacology, 1979, 3, 161-6.	2.3	102
136	Genetics of glucocorticoid-associated osteonecrosis in children with acute lymphoblastic leukemia. Blood, 2015, 126, 1770-1776.	1.4	102
137	Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype. Human Molecular Genetics, 1994, 3, 923-926.	2.9	101
138	Pharmacokinetics of teniposide (VM26) and etoposide (VP16-213) in children with cancer. Cancer Chemotherapy and Pharmacology, 1982, 7, 147-50.	2.3	100
139	Anaphylactoid reactions to escherichia coli and erwinia asparaginase in children with leukemia and lymphoma. Cancer, 1982, 49, 1378-1383.	4.1	99
140	Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism. Lancet Oncology, The, 2010, 11, 507-509.	10.7	97
141	Pharmacokinetics and toxicity of methotrexate in children with Down syndrome and acute lymphocytic leukemia. Journal of Pediatrics, 1987, 111, 606-612.	1.8	95
142	Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquin-oxidation and N-acetylation phenotypes in children. Clinical Pharmacology and Therapeutics, 1989, 45, 568-573.	4.7	95
143	Differences in Folylpolyglutamate Synthetase and Dihydrofolate Reductase Expression in Human B-Lineage versus T-Lineage Leukemic Lymphoblasts: Mechanisms for Lineage Differences in Methotrexate Polyglutamylation and Cytotoxicity. Molecular Pharmacology, 1997, 52, 155-163.	2.3	95
144	A Clinician-Driven Automated System for Integration of Pharmacogenetic Interpretations Into an Electronic Medical Record. Clinical Pharmacology and Therapeutics, 2012, 92, 563-566.	4.7	94

#	Article	IF	Citations
145	Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia. Leukemia, 2012, 26, 2303-2309.	7.2	93
146	Mutational Landscape and Patterns of Clonal Evolution in Relapsed Pediatric Acute Lymphoblastic Leukemia. Blood Cancer Discovery, 2020, 1, 96-111.	5.0	93
147	Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans.. Journal of Clinical Investigation, 1993, 91, 2150-2154.	8.2	92
148	Etoposide pharmacokinetics in patients with normal and abnormal organ function.. Journal of Clinical Oncology, 1986, 4, 1690-1695.	1.6	91
149	A nuclear protein complex containing high mobility group proteins B1 and B2, heat shock cognate protein 70, ERp60, and glyceraldehyde-3-phosphate dehydrogenase is involved in the cytotoxic response to DNA modified by incorporation of anticancer nucleoside analogues. Cancer Research, 2003, 63, 100-6.	0.9	91
150	Outcomes of Growth Hormone Replacement Therapy in Survivors of Childhood Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2002, 20, 2959-2964.	1.6	90
151	Novel variants in NUDT15 and thiopurine intolerance in children with acute lymphoblastic leukemia from diverse ancestry. Blood, 2017, 130, 1209-1212.	1.4	90
152	Reappraisal of the clinical and biologic significance of myeloid-associated antigen expression in childhood acute lymphoblastic leukemia.. Journal of Clinical Oncology, 1998, 16, 3768-3773.	1.6	89
153	Structure and Dynamics of Thioguanine-modified Duplex DNA. Journal of Biological Chemistry, 2003, 278, 1005-1011.	3.4	89
154	Thiopurine pathway. Pharmacogenetics and Genomics, 2010, 20, 573-574.	1.5	89
155	Relation of systemic exposure to unbound etoposide and hematologic toxicity. Clinical Pharmacology and Therapeutics, 1991, 50, 385-393.	4.7	88
156	Clinical and Genetic Risk Factors for Acute Pancreatitis in Patients With Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2016, 34, 2133-2140.	1.6	88
157	Enhanced proteasomal degradation of mutant human thiopurine S-methyltransferase (TPMT) in mammalian cells. Pharmacogenetics and Genomics, 1999, 9, 641-650.	1.5	88
158	De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo. Blood, 2002, 100, 1240-1247.	1.4	87
159	Effect of pleural effusion on highâ€dose methotrexate kinetics. Clinical Pharmacology and Therapeutics, 1978, 23, 68-72.	4.7	85
160	HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies. Blood, 2014, 124, 1266-1276.	1.4	84
161	A substrate specific functional polymorphism of human Î³-glutamyl hydrolase alters catalytic activity and methotrexate polyglutamate accumulation in acute lymphoblastic leukaemia cells. Pharmacogenetics and Genomics, 2004, 14, 557-567.	5.7	83
162	Enhancer Hijacking Drives Oncogenic BCL11B Expression in Lineage-Ambiguous Stem Cell Leukemia. Cancer Discovery, 2021, 11, 2846-2867.	9.4	83

#	Article	IF	Citations
163	ARID5B SNP rs10821936 is associated with risk of childhood acute lymphoblastic leukemia in blacks and contributes to racial differences in leukemia incidence. Leukemia, 2010, 24, 894-896.	7.2	82
164	Altered protein binding of etoposide in patients with cancer. Clinical Pharmacology and Therapeutics, 1989, 45, 49-55.	4.7	81
165	Therapeutic effects and pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor in childhood cancer patients receiving myelosuppressive chemotherapy.. Journal of Clinical Oncology, 1991, 9, 1022-1028.	1.6	81
166	Increased teniposide clearance with concomitant anticonvulsant therapy.. Journal of Clinical Oncology, 1992, 10, 311-315.	1.6	79
167	Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia. Cancer, 2005, 103, 368-376.	4.1	79
168	Methotrexate cerebrospinal fluid and serum concentrations after intermediate-dose methotrexate infusion. Clinical Pharmacology and Therapeutics, 1983, 33, 301-307.	4.7	78
169	Removal of methotrexate, leucovorin, and their metabolites by combined hemodialysis and hemoperfusion. Cancer, 1988, 62, 884-888.	4.1	77
170	A Novel CRM1-mediated Nuclear Export Signal Governs Nuclear Accumulation of Glyceraldehyde-3-phosphate Dehydrogenase following Genotoxic Stress. Journal of Biological Chemistry, 2004, 279, 5984-5992.	3.4	77
171	Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia. Blood, 2012, 119, 1658-1664.	1.4	77
172	Changes in the clearance of total and unbound etoposide in patients with liver dysfunction.. Journal of Clinical Oncology, 1990, 8, 1874-1879.	1.6	76
173	Isolation of a human thiopurine S-methyltransferase (TPMT) complementary DNA with a single nucleotide transition A719G (TPMT*3C) and its association with loss of TPMT protein and catalytic activity in humans*. Clinical Pharmacology and Therapeutics, 1998, 64, 46-51.	4.7	76
174	BCR-ABL1-like cases in pediatric acute lymphoblastic leukemia: a comparison between DCOG/Erasmus MC and COG/St. Jude signatures. Haematologica, 2015, 100, e354-e357.	3.5	76
175	Outcome of children with hypodiploid ALL treated with risk-directed therapy based on MRD levels. Blood, 2015, 126, 2896-2899.	1.4	76
176	In Vivo Response to Methotrexate Forecasts Outcome of Acute Lymphoblastic Leukemia and Has a Distinct Gene Expression Profile. PLoS Medicine, 2008, 5, e83.	8.4	75
177	Higher activity of polymorphic thiopurine S-methyltransferase in erythrocytes from neonates compared to adults. Pharmacogenetics and Genomics, 1995, 5, 281-286.	5.7	74
178	Karyotypic abnormalities create discordance of germline genotype and cancer cell phenotypes. Nature Genetics, 2005, 37, 878-882.	21.4	72
179	Inherited coding variants at the CDKN2A locus influence susceptibility to acute lymphoblastic leukaemia in children. Nature Communications, 2015, 6, 7553.	12.8	72
180	Molecular haplotyping of genomic DNA for multiple single-nucleotide polymorphisms located kilobases apart using long-range polymerase chain reaction and intramolecular ligation. Pharmacogenetics and Genomics, 2002, 12, 93-99.	5.7	71

#	Article	IF	Citations
181	Aspirin alters methotrexate disposition in rheumatoid arthritis patients. Arthritis and Rheumatism, 1991, 34, 1514-1520.	6.7	71
182	Asparagine synthetase expression is linked with L-asparaginase resistance in TEL-AML1-negative but not TEL-AML1-positive pediatric acute lymphoblastic leukemia. Blood, 2005, 105, 4223-4225.	1.4	70
183	Risk of Adverse Events After Completion of Therapy for Childhood Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2005, 23, 7936-7941.	1.6	70
184	Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia. Nature Cancer, 2021, 2, 284-299.	13.2	70
185	Methotrexate bioavailability after oral and intramuscular administration in children. Journal of Pediatrics, 1987, 110, 788-792.	1.8	69
186	Genetic Variations in GRIA1 on Chromosome 5q33 Related to Asparaginase Hypersensitivity. Clinical Pharmacology and Therapeutics, 2010, 88, 191-196.	4.7	69
187	Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia.. Journal of Clinical Oncology, 1996, 14, 1504-1511.	1.6	67
188	Genome-wide analysis links NFATC2 with asparaginase hypersensitivity. Blood, 2015, 126, 69-75.	1.4	64
189	High-dose dextromethorphan in amyotrophic lateral sclerosis: Phase I safety and pharmacokinetic studies. Annals of Neurology, 1994, 36, 920-924.	5.3	63
190	Pharmacokinetics of Anticancer Drugs in Children. Clinical Pharmacokinetics, 1987, 12, 168-213.	3.5	62
191	MicroRNAs Form Triplexes with Double Stranded DNA at Sequence-Specific Binding Sites; a Eukaryotic Mechanism via which microRNAs Could Directly Alter Gene Expression. PLoS Computational Biology, 2016, 12, e1004744.	3.2	62
192	High-dose methotrexate improves clinical outcome in children with acute lymphoblastic leukemia: St. Jude total therapy study X. Medical and Pediatric Oncology, 1988, 16, 297-303.	1.0	61
193	The SWI/SNF Chromatin-Remodeling Complex and Glucocorticoid Resistance in Acute Lymphoblastic Leukemia. Journal of the National Cancer Institute, 2008, 100, 1792-1803.	6.3	61
194	Antibodies Predict Pegaspargase Allergic Reactions and Failure of Rechallenge. Journal of Clinical Oncology, 2019, 37, 2051-2061.	1.6	61
195	Disposition of recombinant human granulocyte colony-stimulating factor in children with severe chronic neutropenia. Journal of Pediatrics, 1993, 123, 471-479.	1.8	59
196	Etoposide achieves potentially cytotoxic concentrations in CSF of children with acute lymphoblastic leukemia.. Journal of Clinical Oncology, 1996, 14, 399-404.	1.6	59
197	Second malignancy after treatment of childhood non-Hodgkin lymphoma. Cancer, 2001, 92, 1959-1966.	4.1	59
198	Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes. Pharmacogenomics, 2014, 15, 1065-1078.	1.3	59

#	Article	IF	Citations
199	High-Performance Liquid Chromatographic Analysis of the Semisynthetic Epipodophyllotoxins Teniposide and Etoposide Using Electrochemical Detection. Journal of Pharmaceutical Sciences, 1984, 73, 164-168.	3.3	58
200	Identification of four novel associations for B-cell acute lymphoblastic leukaemia risk. Nature Communications, 2019, 10, 5348.	12.8	58
201	Coadministration of naproxen and low-dose methotrexate in patients with rheumatoid arthritis. Clinical Pharmacology and Therapeutics, 1990, 47, 540-546.	4.7	56
202	PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity. Human Molecular Genetics, 2012, 21, 4793-4804.	2.9	56
203	Pharmacogenetics in Acute Lymphoblastic Leukemia. Seminars in Hematology, 2009, 46, 39-51.	3.4	55
204	Molecular diagnostics as a predictive tool: genetics of drug efficacy and toxicity. Trends in Molecular Medicine, 2002, 8, 300-305.	6.7	54
205	Childhood acute lymphoblastic leukemia. Reviews in Clinical and Experimental Hematology, 2002, 6, 161-180.	0.1	53
206	Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment. Blood, 2005, 106, 1778-1785.	1.4	53
207	Acquired variation outweighs inherited variation in whole genome analysis of methotrexate polyglutamate accumulation in leukemia. Blood, 2009, 113, 4512-4520.	1.4	52
208	Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase status. Expert Opinion on Drug Safety, 2010, 9, 23-37.	2.4	52
209	Loss of TBL1XR1 Disrupts Glucocorticoid Receptor Recruitment to Chromatin and Results in Glucocorticoid Resistance in a B-Lymphoblastic Leukemia Model. Journal of Biological Chemistry, 2014, 289, 20502-20515.	3.4	52
210	A Novel Protein Complex Distinct from Mismatch Repair Binds Thioguanylated DNA. Molecular Pharmacology, 2001, 59, 367-374.	2.3	51
211	An Inherited Genetic Variant in CEP72 Promoter Predisposes to Vincristineâ€Induced Peripheral Neuropathy in Adults With Acute Lymphoblastic Leukemia. Clinical Pharmacology and Therapeutics, 2017, 101, 391-395.	4.7	51
212	Adjuvant chemotherapy for osteosarcoma of the extremity long-term results of two consecutive prospective protocol studies. Cancer, 1990, 65, 439-445.	4.1	48
213	The effect of prior cisplatin therapy on the pharmacokinetics of high-dose methotrexate.. Journal of Clinical Oncology, 1984, 2, 655-661.	1.6	47
214	Promoter and intronic sequences of the human thiopurine S-methyltransferase (TPMT) gene isolated from a human PAC1 genomic library. Pharmaceutical Research, 1997, 14, 1672-1678.	3.5	47
215	A genome-wide approach identifies that the aspartate metabolism pathway contributes to asparaginase sensitivity. Leukemia, 2011, 25, 66-74.	7.2	47
216	HPLC Determination of Thiopurine Nucleosides and Nucleotides in Vivo in Lymphoblasts following Mercaptopurine Therapy. Clinical Chemistry, 2002, 48, 61-68.	3.2	46

#	Article	IF	Citations
217	Modeling Mechanisms of In Vivo Variability in Methotrexate Accumulation and Folate Pathway Inhibition in Acute Lymphoblastic Leukemia Cells. PLoS Computational Biology, 2010, 6, e1001019.	3.2	46
218	Enhanced hepatic drug clearance in patients with cystic fibrosis. Journal of Pediatrics, 1990, 117, 972-979.	1.8	45
219	Persistence of lymphoblasts in bone marrow on day 15 and days 22 to 25 of remission induction predicts a dismal treatment outcome in children with acute lymphoblastic leukemia. Blood, 2002, 100, 43-47.	1.4	45
220	Shortening Infusion Time for High-Dose Methotrexate Alters Antileukemic Effects: A Randomized Prospective Clinical Trial. Journal of Clinical Oncology, 2011, 29, 1771-1778.	1.6	45
221	Age-related differences in hepatic drug clearance in children: Studies with lorazepam and antipyrine. Clinical Pharmacology and Therapeutics, 1991, 50, 132-140.	4.7	44
222	Role of pharmacogenomics and pharmacodynamics in the treatment of acute lymphoblastic leukaemia. Best Practice and Research in Clinical Haematology, 2002, 15, 741-756.	1.7	44
223	Novel susceptibility variants at the ERG locus for childhood acute lymphoblastic leukemia in Hispanics. Blood, 2019, 133, 724-729.	1.4	44
224	Integrative genomic analyses reveal mechanisms of glucocorticoid resistance in acute lymphoblastic leukemia. Nature Cancer, 2020, 1, 329-344.	13.2	44
225	A mathematical model of in vivo methotrexate accumulation in acute lymphoblastic leukemia. Cancer Chemotherapy and Pharmacology, 2002, 50, 419-428.	2.3	43
226	Lead Poisoning from Ingestion of Chinese Herbal Medicine. Clinical Toxicology, 1977, 10, 273-281.	0.5	42
227	Clinical pharmacodynamics of anticancer drugs: a basis for extending the concept of dose-intensity. Blut, 1988, 56, 241-248.	1.2	41
228	Peripheral neuropathy in children and adolescents treated for cancer. The Lancet Child and Adolescent Health, 2018, 2, 744-754.	5.6	41
229	A Model for Dosing Gentamicin in Children and Adolescents that Adjusts for Tissue Accumulation with Continuous Dosing1. Clinical Pharmacokinetics, 1980, 5, 295-306.	3.5	40
230	Simultaneous administration of multiple model substrates to assess hepatic drug clearance. Clinical Pharmacology and Therapeutics, 1987, 41, 645-650.	4.7	39
231	Unravelling the functional genomics of the human CYP2D6 gene locus. Pharmacogenetics and Genomics, 2001, 11, 553-554.	5.7	39
232	Differential Effects of Targeted Disruption of Thiopurine Methyltransferase on Mercaptopurine and Thioguanine Pharmacodynamics. Cancer Research, 2007, 67, 4965-4972.	0.9	39
233	Unexpectedly severe toxicity from intensive early treatment of childhood lymphoblastic leukemia.. Journal of Clinical Oncology, 1985, 3, 201-206.	1.6	38
234	Acute lymphoblastic leukemia with TEL-AML1 fusion has lower expression of genes involved in purine metabolism and lower de novo purine synthesis. Blood, 2004, 104, 1435-1441.	1.4	38

#	Article	IF	Citations
235	Pharmacogenomics of acute lymphoblastic leukemia. Current Opinion in Hematology, 2006, 13, 260-265.	2.5	38
236	Expression of SMARCB1 modulates steroid sensitivity in human lymphoblastoid cells: identification of a promoter snp that alters PARP1 binding and SMARCB1 expression. Human Molecular Genetics, 2007, 16, 2261-2271.	2.9	38
237	Asparaginase formulation impacts hypertriglyceridemia during therapy for acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2020, 67, e28040.	1.5	38
238	Methotrexate intracellular disposition in acute lymphoblastic leukemia: a mathematical model of gamma-glutamyl hydrolase activity. Clinical Cancer Research, 2002, 8, 2423-9.	7.0	38
239	Lorazepam pharmacodynamics and pharmacokinetics in children. Journal of Pediatrics, 1989, 114, 641-646.	1.8	37
240	PHARMACOGENOMICS OF ACUTE LEUKEMIA. Annual Review of Pharmacology and Toxicology, 2006, 46, 317-353.	9.4	37
241	Cisplatin disposition in children and adolescents with cancer. Cancer Chemotherapy and Pharmacology, 1981, 6, 95-9.	2.3	36
242	Hepatic drug clearance in children with leukemia: Changes in clearance of model substrates during remission-induction therapy. Clinical Pharmacology and Therapeutics, 1987, 41, 651-660.	4.7	36
243	Concept of maximum tolerated systemic exposure and its application to phase I-II studies of anticancer drugs. Medical and Pediatric Oncology, 1991, 19, 153-159.	1.0	36
244	Between-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustments. Cancer Chemotherapy and Pharmacology, 2013, 72, 369-378.	2.3	36
245	Hepatic Drug Clearance in Children: Studies with Indocyanine Green as a Model Substrate. Journal of Pharmaceutical Sciences, 1989, 78, 452-456.	3.3	35
246	Risk of adverse events in children completing treatment for acute lymphoblastic leukemia: St. Jude Total Therapy studies VIII, IX, and X.. Journal of Clinical Oncology, 1991, 9, 1341-1347.	1.6	35
247	Association of Genetic Ancestry With the Molecular Subtypes and Prognosis of Childhood Acute Lymphoblastic Leukemia. JAMA Oncology, 2022, 8, 354.	7.1	35
248	Hepatotoxicity of 6-mercaptopurine in childhood acute lymphocytic leukemia: Pharmacokinetic characteristics. , 1996, 26, 85-89.		34
249	Cancer Pharmacogenomics. Clinical Pharmacology and Therapeutics, 2011, 90, 461-466.	4.7	34
250	Clinical pharmacology of bleomycin and cisplatin. Head & Neck, 1981, 4, 98-110.	0.3	33
251	Pharmacogenomics: marshalling the human genome to individualise drug therapy. Gut, 2003, 52, 10ii-18.	12.1	33
252	Pharmacogenomics in cancer therapy: is host genome variability important?. Trends in Pharmacological Sciences, 2004, 25, 457-464.	8.7	33

#	Article	IF	Citations
253	Prognostic Importance of 6-Mercaptopurine Dose Intensity in Acute Lymphoblastic Leukemia. Blood, 1999, 93, 2817-2823.	1.4	33
254	Epigenetic Regulation of Human Î³-Glutamyl Hydrolase Activity in Acute Lymphoblastic Leukemia Cells. American Journal of Human Genetics, 2006, 79, 264-274.	6.2	32
255	Comparison of self-report and electronic monitoring of 6MP intake in childhood ALL: a Childrenâ€™s Oncology Group study. Blood, 2017, 129, 1919-1926.	1.4	32
256	Genome-Wide Association Study of Susceptibility Loci for T-Cell Acute Lymphoblastic Leukemia in Children. Journal of the National Cancer Institute, 2019, 111, 1350-1357.	6.3	32
257	Clinical Pharmacology of Cancer Chemotherapy in Children. Pediatric Clinics of North America, 1989, 36, 1199-1230.	1.8	31
258	Functional characterization of the human thiopurine S-methyltransferase (TPMT) gene promoter. FEBS Journal, 1998, 256, 510-517.	0.2	31
259	Enhanced proteasomal degradation of mutant human thiopurine S-methyltransferase (TPMT) in mammalian cells. Pharmacogenetics and Genomics, 1999, 9, 641???650.	5.7	31
260	Gene expression as a drug discovery tool. Nature Genetics, 2004, 36, 214-215.	21.4	30
261	Lymphoid gene expression as a predictor of risk of secondary brain tumors. Genes Chromosomes and Cancer, 2005, 42, 107-116.	2.8	30
262	Pharmacokinetics of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor in Children after Intravenous and Subcutaneous Administration. Journal of Pharmaceutical Sciences, 1995, 84, 824-828.	3.3	29
263	Rapid genotyping of common deficient thiopurine S-methyltransferase alleles using the DNA-microchip technique. European Journal of Human Genetics, 2006, 14, 991-998.	2.8	29
264	Noncoding genetic variation in GATA3 increases acute lymphoblastic leukemia risk through local and global changes in chromatin conformation. Nature Genetics, 2022, 54, 170-179.	21.4	29
265	Use of gentamicin serum levels to individualize therapy in children. Journal of Pediatrics, 1978, 93, 133-137.	1.8	28
266	Pharmacogenomics in pediatric leukemia. Current Opinion in Pediatrics, 2010, 22, 703-710.	2.0	28
267	ARID5B Regulates Leukemia Sensitivity to Antimetabolites in Children with Acute Lymphoblastic Leukemia Via Effects on Cell Cycle Progression. Blood, 2014, 124, 791-791.	1.4	28
268	Acute Lymphoblastic Leukemia in Infants. Journal of Clinical Oncology, 1999, 17, 438-438.	1.6	27
269	Quantitation of daunorubicin and its metabolites by high-performance liquid chromatography with electrochemical detection. Biomedical Applications, 1982, 232, 377-383.	1.7	26
270	Escalating teniposide systemic exposure to increase dose intensity for pediatric cancer patients.. Journal of Clinical Oncology, 1993, 11, 287-293.	1.6	26

#	Article	IF	Citations
271	TPMT genetic variations in populations of the Russian Federation. Pediatric Blood and Cancer, 2009, 52, 203-208.	1.5	26
272	Mercaptopurine Ingestion Habits, Red Cell Thioguanine Nucleotide Levels, and Relapse Risk in Children With Acute Lymphoblastic Leukemia: A Report From the Childrenâ€™s Oncology Group Study AALL03N1. Journal of Clinical Oncology, 2017, 35, 1730-1736.	1.6	26
273	Reappraisal of Guidelines for Pharmacokinetic Monitoring of Aminoglycosides. Pharmacotherapy, 1981, 1, 55-75.	2.6	25
274	ARID5B Influences Antimetabolite Drug Sensitivity and Prognosis of Acute Lymphoblastic Leukemia. Clinical Cancer Research, 2020, 26, 256-264.	7.0	25
275	Disposition of Intermediate-Dose Methotrexate in Children with Acute Lymphocytic Leukemia. Drug Intelligence & Clinical Pharmacy, 1982, 16, 839-842.	0.4	24
276	Thiopurine S-methyltransferase: a genetic polymorphism that affects a small number of drugs in a big way. Pharmacogenetics and Genomics, 2002, 12, 421-423.	5.7	24
277	The synergism of MCL1 and glycolysis on pediatric acute lymphoblastic leukemia cell survival and prednisolone resistance. Haematologica, 2013, 98, 1905-1911.	3.5	23
278	Pharmacokinetics of Anticancer Drugs in Children. Drug Metabolism Reviews, 1983, 14, 847-886.	3.6	22
279	Mercaptopurine vs thioguanine for the treatment of acute lymphoblastic leukemia. Leukemia Research, 1994, 18, 811-814.	0.8	22
280	Differing effects of methylenetetrahydrofolate reductase single nucleotide polymorphisms on methotrexate efficacy and toxicity in rheumatoid arthritis. Pharmacogenetics and Genomics, 2002, 12, 181-182.	5.7	22
281	Genome-wide CRISPR screen reveals PSMA6 to be an essential gene in pancreatic cancer cells. BMC Cancer, 2019, 19, 253.	2.6	22
282	High-performance liquid chromatographic assay of methotrexate, 7-hydroxymethotrexate, 4-deoxy-4-amino-N10-methylpteroic acid and sulfamethoxazole in serum, urine and cerebrospinal fluid. Biomedical Applications, 1982, 231, 103-110.	1.7	21
283	High-performance liquid chromatographic assay for cytosine arabinoside, uracil arabinoside and some related nucleosides. Biomedical Applications, 1983, 274, 87-93.	1.7	21
284	Hepatic drug clearance in patients with mild cystic fibrosis*. Clinical Pharmacology and Therapeutics, 1996, 59, 529-540.	4.7	21
285	The Promise and the Reality of Genomics to Guide Precision Medicine in Pediatric Oncology: The Decade Ahead. Clinical Pharmacology and Therapeutics, 2020, 107, 176-180.	4.7	21
286	Loop-Column Extraction and Liquid Chromatographic Analysis of Doxorubicin and Three Metabolites in Plasma. Therapeutic Drug Monitoring, 1985, 7, 455-460.	2.0	20
287	Expression of the outcome predictor in acute leukemia 1 (OPAL1) gene is not an independent prognostic factor in patients treated according to COALL or St Jude protocols. Blood, 2006, 108, 1984-1990.	1.4	20
288	A Health-Care System Perspective on Implementing Genomic Medicine: Pediatric Acute Lymphoblastic Leukemia as a Paradigm. Clinical Pharmacology and Therapeutics, 2013, 94, 224-229.	4.7	20

#	Article	IF	Citations
289	Germline RUNX1 variation and predisposition to childhood acute lymphoblastic leukemia. Journal of Clinical Investigation, 2021, 131, .	8.2	20
290	ASHP Foundation Pharmacy Forecast 2018: Strategic Planning Advice for Pharmacy Departments in Hospitals and Health Systems. American Journal of Health-System Pharmacy, 2018, 75, 23-54.	1.0	19
291	Population Pharmacokinetics of Vincristine Related to Infusion Duration and Peripheral Neuropathy in Pediatric Oncology Patients. Cancers, 2020, 12, 1789.	3.7	18
292	Pharmacogenomics of intracellular methotrexate polyglutamates in patientsâ€™ leukemia cells in vivo. Journal of Clinical Investigation, 2020, 130, 6600-6615.	8.2	18
293	Bleomycin disposition in children with cancer. Clinical Pharmacology and Therapeutics, 1983, 33, 668-673.	4.7	17
294	A Longitudinal Study of Granulocyte Colony-Stimulating Factor Levels and Neutrophil Counts in Newborn Infants. Journal of Pediatric Hematology/Oncology, 1995, 17, 176-179.	0.6	17
295	Genetics of pleiotropic effects of dexamethasone. Pharmacogenetics and Genomics, 2017, 27, 294-302.	1.5	17
296	Gentamicin dosage in children: A randomized prospective comparison of body weight and body surface area as dose determinants. Journal of Pediatrics, 1979, 94, 139-143.	1.8	16
297	Pharmacokinetics of Sustained Serum Methotrexate Concentrations Secondary to Gastrointestinal Obstruction. Journal of Pharmaceutical Sciences, 1981, 70, 1194-1198.	3.3	16
298	Simultaneous analysis of antipyrine and lorazepam by high-performance liquid chromatography. Biomedical Applications, 1986, 382, 199-205.	1.7	16
299	Factors Affecting In Vitro Protein Binding of Etoposide in Humans. Journal of Pharmaceutical Sciences, 1992, 81, 259-264.	3.3	16
300	Does pharmacokinetic variability influence the efficacy of high-dose methotrexate for the treatment of children with acute lymphoblastic leukemia: What can we learn from small studies?. Leukemia Research, 1997, 21, 435-437.	0.8	16
301	Effect of Premedications in a Murine Model of Asparaginase Hypersensitivity. Journal of Pharmacology and Experimental Therapeutics, 2015, 352, 541-551.	2.5	16
302	Association ofGATA3Polymorphisms With Minimal Residual Disease and Relapse Risk in Childhood Acute Lymphoblastic Leukemia. Journal of the National Cancer Institute, 2021, 113, 408-417.	6.3	16
303	HPLC determination of thiopurine nucleosides and nucleotides in vivo in lymphoblasts following mercaptopurine therapy. Clinical Chemistry, 2002, 48, 61-8.	3.2	16
304	A Simple Preparation of the Methotrexate Metabolites 7-Hydroxymethotrexate and 4-Deoxy-4-amino-N10-methylpteroic Acid. Therapeutic Drug Monitoring, 1983, 5, 363-366.	2.0	15
305	Global gene expression as a function of germline genetic variation. Human Molecular Genetics, 2005, 14, 1621-1629.	2.9	15
306	Pharmacogenomics of Vincristineâ€Induced Peripheral Neuropathy: Progress Continues. Clinical Pharmacology and Therapeutics, 2019, 105, 315-317.	4.7	15

#	Article	IF	Citations
307	Profiling chromatin accessibility in pediatric acute lymphoblastic leukemia identifies subtype-specific chromatin landscapes and gene regulatory networks. Leukemia, 2021, 35, 3078-3091.	7.2	15
308	Phenobarbital-Induced Hepatic Dysfunction. Drug Intelligence & Clinical Pharmacy, 1976, 10, 439-443.	0.4	14
309	Use of the automatic interaction detector method to identify patient characteristics related to methotrexate clearance. Clinical Pharmacology and Therapeutics, 1986, 39, 592-597.	4.7	14
310	Antagonism by methotrexate on mercaptopurine disposition in lymphoblasts during up-front treatment of acute lymphoblastic leukemia. Clinical Pharmacology and Therapeutics, 2003, 73, 506-516.	4.7	14
311	Statement by members of the Ponte di Legno Group on the right of children to have full access to essential treatment for acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2004, 43, 103-104.	1.5	14
312	Vincristine pharmacogenomics. Pharmacogenetics and Genomics, 2016, 26, 51-52.	1.5	14
313	Accuracy of Using Pre- and Postdose Gentamicin Serum Concentrations to Estimate Pharmacokinetic Parameters and Adjust Doses in Children and Adolescents. Therapeutic Drug Monitoring, 1981, 3, 57-62.	2.0	14
314	Alteration of RNA Splicing by Small-Molecule Inhibitors of the Interaction between NHP2L1 and U4. SLAS Discovery, 2018, 23, 164-173.	2.7	14
315	Characterization of Novel Subtypes in B Progenitor Acute Lymphoblastic Leukemia. Blood, 2018, 132, 565-565.	1.4	14
316	Effect of hepatic irradiation on the toxicity and pharmacokinetics of adriamycin in children. International Journal of Radiation Oncology Biology Physics, 1981, 7, 953-956.	0.8	13
317	Clinical Pharmacology of Bleomycin and Cisplatin. Drug Intelligence & Clinical Pharmacy, 1982, 16, 448-458.	0.4	13
318	In Vivo., Toxicity and Pharmacokinetic Features of B43(Anti-CD19)-Genistein Immunoconjugate. Leukemia and Lymphoma, 1998, 30, 389-394.	1.3	13
319	Deoxythioguanosine triphosphate impairs HIV replication: a new mechanism for an old drug. FASEB Journal, 2001, 15, 1902-1908.	0.5	13
320	Hypomethylation of NLRP3 gene promoter discriminates glucocorticoidâ€resistant from glucocorticoidâ€sensitive idiopathic nephrotic syndrome patients. Clinical and Translational Science, 2021, 14, 964-975.	3.1	13
321	Comprehensive Assessment of Thiopurine S-Methyltransferase (TPMT) Alleles in Three Ethnic Populations. Journal of Pediatric Hematology/Oncology, 2002, 24, 335-336.	0.6	13
322	Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia. Blood, 2000, 96, 3381-3384.	1.4	13
323	Antileukemic Efficacy of Continuous vs Discontinuous Dexamethasone in Murine Models of Acute Lymphoblastic Leukemia. PLoS ONE, 2015, 10, e0135134.	2.5	13
324	High-performance liquid chromatographic assay of mitomycin in biological fluids. Biomedical Applications, 1985, 345, 197-202.	1.7	12

#	Article	IF	Citations
325	Identification of small molecules that mitigate vincristineâ€induced neurotoxicity while sensitizing leukemia cells to vincristine. Clinical and Translational Science, 2021, 14, 1490-1504.	3.1	12
326	Alternative Approaches for Phase I Studies of Anticancer Drugs. Therapeutic Drug Monitoring, 1993, 15, 492-497.	2.0	11
327	Msh2 Deficiency Attenuates But Does Not Abolish Thiopurine Hematopoietic Toxicity inMsh2-/-Mice. Molecular Pharmacology, 2003, 64, 456-465.	2.3	11
328	Cancer Pharmacogenomics May Require Both Qualitative and Quantitative Approaches. Cell Cycle, 2005, 4, 1506-1509.	2.6	11
329	Pharm.D.-Only Investigators Are Critical to the Profession: Let's Preserve the Fellowship as an Equally Important Way to Prepare Future Clinical Pharmaceutical Scientists: Or the Case Against the â€œAll-Ph.D.â€. Pharmacotherapy, 2009, 29, 129-133.	2.6	11
330	Integrated analysis of pharmacologic, clinical and SNP microarray data using Projection Onto the Most Interesting Statistical Evidence with Adaptive Permutation Testing. International Journal of Data Mining and Bioinformatics, 2011, 5, 143.	0.1	11
331	Leukemia Cells with a BCR-ABL1-Like signature and/or IKZF1 deletions, but Not High CRLF2 Expression, Are Predictive of an Unfavorable Prognosis in Childhood B Cell Precursor Acute Lymphoblastic Leukemia. Blood, 2012, 120, 880-880.	1.4	11
332	Favorable Pharmacodynamic Features and Superior Anti-Leukemic Activity of B43 (Anti-CD 19) Immunotoxins Containing Two Pokeweed Antiviral Protein Molecules Covalently Linked to each Monoclonal Antibody Molecule. Leukemia and Lymphoma, 1995, 18, 93-102.	1.3	10
333	Molecular cloning and functional characterization of the cDNA encoding the murine thiopurineS-methyltransferase (TPMT). FEBS Letters, 1998, 424, 143-145.	2.8	10
334	Is mega dose of methotrexate beneficial to patients with acute lymphoblastic leukemia?. Leukemia and Lymphoma, 2006, 47, 2431-2432.	1.3	10
335	Differential effects of thiopurine methyltransferase (TPMT) and multidrug resistance-associated protein gene 4 (MRP4) on mercaptopurine toxicity. Cancer Chemotherapy and Pharmacology, 2017, 80, 287-293.	2.3	10
336	Host thiopurine methyltransferase status affects mercaptopurine antileukemic effectiveness in a murine model. Pharmacogenetics and Genomics, 2014, 24, 263-271.	1.5	9
337	Inflammasome-mediated glucocorticoid resistance: The receptor rheostat. Molecular and Cellular Oncology, 2016, 3, e1065947.	0.7	9
338	Genome-Wide Association Study of Susceptibility Loci for TCF3-PBX1 Acute Lymphoblastic Leukemia in Children. Journal of the National Cancer Institute, 2021, 113, 933-937.	6.3	9
339	The Clinical Pharmacist and Research. Journal of Clinical Pharmacology, 1981, 21, 241-244.	2.0	8
340	Closing the gap between science and clinical practice. Pharmacogenetics and Genomics, 2004, 14, 395-396.	5.7	8
341	Concordant Gene Expression in Leukemia Cells and Normal Leukocytes Is Associated with Germline cis-SNPs. PLoS ONE, 2008, 3, e2144.	2.5	8
342	Epigenetic Regulation of Human Î³-Glutamyl Hydrolase Activity in Acute Lymphoblastic Leukemia Cells. American Journal of Human Genetics, 2010, 87, 161.	6.2	8

#	Article	IF	Citations
343	Individual prediction of nonadherence to oral mercaptopurine in children with acute lymphoblastic leukemia: Results from COG AALL03N1. Cancer, 2021, 127, 3832-3839.	4.1	8
344	Genetic Abnormalities and Drug Resistance in Acute Lymphoblastic Leukemia. Advances in Experimental Medicine and Biology, 1999, 457, 383-389.	1.6	8
345	Higher Frequency of Glutathione S-Transferase Deletions in Black Children With Acute Lymphoblastic Leukemia. Blood, 1997, 89, 1701-1707.	1.4	8
346	A Whole Genome Analysis Identifies SLCO1B1 as a Determinant of Methotrexate Pharmacokinetics and Adverse Effects. Blood, 2008, 112, 214-214.	1.4	8
347	Amino acid stress response genes promote L-asparaginase resistance in pediatric acute lymphoblastic leukemia. Blood Advances, 2022, 6, 3386-3397.	5.2	8
348	Anticancer Therapy as a Pediatric Pharmacodynamic Paradigm. Developmental Pharmacology and Therapeutics, 1989, 13, 85-95.	0.2	7
349	Synthesis of potential antifilarial agents 2 . methyl 2â€substituted purine 8â€carbamates and related compounds. Journal of Heterocyclic Chemistry, 1989, 26, 1053-1059.	2.6	7
350	Improved high-performance liquid chromatographic method using loop-column extraction for analysis of idarubicin and idarubicinol in plasma. Biomedical Applications, 1989, 491, 501-506.	1.7	7
351	Pharmacokinetics of continuous-infusion amsacrine and teniposide for the treatment of relapsed childhood acute nonlymphocytic leukemia. Cancer Chemotherapy and Pharmacology, 1991, 27, 397-400.	2.3	7
352	Asparaginase combined with discontinuous dexamethasone improves antileukemic efficacy without increasing osteonecrosis in preclinical models. PLoS ONE, 2019, 14, e0216328.	2.5	7
353	miR-331-3p is involved in glucocorticoid resistance reversion by rapamycin through suppression of the MAPK signaling pathway. Cancer Chemotherapy and Pharmacology, 2020, 86, 361-374.	2.3	7
354	Fluoroquinolone prophylaxis does not increase risk of neuropathy in children with acute lymphoblastic leukemia. Cancer Medicine, 2020, 9, 6550-6555.	2.8	7
355	Class II Human Leukocyte Antigen Variants Associate With Risk of Pegaspargase Hypersensitivity. Clinical Pharmacology and Therapeutics, 2021, 110, 794-802.	4.7	7
356	Comprehensive characterization of pharmacogenetic variants in TPMT and NUDT15 in children with acute lymphoblastic leukemia. Pharmacogenetics and Genomics, 2022, 32, 60-66.	1.5	7
357	Lipoprotein Analysis in the Evaluation of Chest Pain in the Emergency Department. Mayo Clinic Proceedings, 1991, 66, 885-891.	3.0	6
358	Mathematical modeling of folate metabolism. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2013, 5, 603-613.	6.6	6
359	Genome-Wide Association Analyses Identify Susceptibility Loci For Vincristine-Induced Peripheral Neuropathy In Children With Acute Lymphoblastic Leukemia. Blood, 2013, 122, 618-618.	1.4	6
360	Early Intensification of Intrathecal Chemotherapy Virtually Eliminates Central Nervous System Relapse in Children With Acute Lymphoblastic Leukemia. Blood, 1998, 92, 411-415.	1.4	6

#	Article	IF	Citations
361	Genetic Variation in NFATC2 Is Associated with a Higher Risk of Asparaginase Allergy. Blood, 2014, 124, 63-63.	1.4	6
362	Effects of NT5C2 Germline Variants on 6â€Mecaptopurine Metabolism in Children With Acute Lymphoblastic Leukemia. Clinical Pharmacology and Therapeutics, 2021, 109, 1538-1545.	4.7	5
363	Comprehensive analysis of dose intensity of acute lymphoblastic leukemia chemotherapy. Haematologica, 2022, 107, 371-380.	3.5	5
364	Defining the Optimal Dosage of Methotrexate for Childhood Acute Lymphoblastic Leukemia. Advances in Experimental Medicine and Biology, 1999, 457, 537-541.	1.6	5
365	A Genome-Wide Analysis of Variants Influencing Methotrexate Clearance Replicates SLCO1B1.. Blood, 2012, 120, 2466-2466.	1.4	5
366	High Intra-Individual Variability In Systemic Exposure To 6 Mercaptopurine (6MP) In Children With Acute Lymphoblastic Leukemia (ALL) Contributes To ALL Relapse: Results From a Childrenâ€™s Oncology Group (COG) Study (AALL03N1). Blood, 2013, 122, 59-59.	1.4	5
367	Identification of Gene Expression Profiles in Acute Lymphoblastic Leukemia Cells That Discriminate Intracellular Thioguanine Nucleotide Accumulation in ALL Cells after In Vivo Treatment with Mercaptopurine.. Blood, 2004, 104, 453-453.	1.4	5
368	The Genomic Landscape of Childhood Acute Lymphoblastic Leukemia. Blood, 2019, 134, 649-649.	1.4	5
369	Molybdenum Cofactor Catabolism Unravels the Physiological Role of the Drug Metabolizing Enzyme Thiopurine Sâ€Methyltransferase. Clinical Pharmacology and Therapeutics, 2022, 112, 808-816.	4.7	5
370	Double-blind evaluation of 5-Î¼m final filtration to reduce postinfusion phlebitis. American Journal of Health-System Pharmacy, 1976, 33, 1160-1163.	1.0	4
371	Resequencing the sulfotransferase SULT1 gene provides new insights, while illuminating challenges that lie ahead for pharmacogenomics. Pharmacogenetics and Genomics, 2001, 11, 745-746.	5.7	4
372	Expression arrays illuminate a way forward for mantle cell lymphoma. Cancer Cell, 2003, 3, 100-102.	16.8	4
373	TELAML1-Positive ALL: A Discordant Genotype. Cell Cycle, 2005, 4, 997-998.	2.6	4
374	Are children with lesser-risk B-lineage acute lymphoblastic leukemia curable with antimetabolite therapy?. Nature Clinical Practice Oncology, 2008, 5, 130-131.	4.3	4
375	A p53-regulated apoptotic gene signature predicts treatment response and outcome in pediatric acute lymphoblastic leukemia. Cancer Management and Research, 2017, Volume 9, 397-410.	1.9	4
376	Pharmacodynamic Monitoring of Cancer Chemotherapy: Childhood Acute Lymphoblastic Leukemia as a Model. Therapeutic Drug Monitoring, 1998, 20, 453-458.	2.0	4
377	VPREB1 Deletions Occur Independent of Lambda-Light Chain Rearrangement and Predict Worse Outcome In Pediatric Acute Lymphoblastic Leukemia (ALL). Blood, 2010, 116, 273-273.	1.4	4
378	A Journey from Pediatric Pharmacokinetics to Pharmacogenomics. Journal of Pediatric Pharmacology and Therapeutics, 2005, 10, 8-13.	0.5	4

#	Article	IF	Citations
379	Association between CEP72 genotype and persistent neuropathy in survivors of childhood acute lymphoblastic leukemia. Leukemia, 2022, 36, 1160-1163.	7.2	4
380	Synthesis of Modified Thiopurine Nucleosides for Structural Characterization of Human Thiopurine S-Methyltransferase. Nucleosides & Nucleotides, 1999, 18, 1747-1748.	0.5	3
381	High-dose Methotrexate: The Rationaleâ€¦. Journal of Pediatric Hematology/Oncology, 2009, 31, 224-225.	0.6	3
382	Msh2 deficiency leads to dysmyelination of the corpus callosum, impaired locomotion and altered sensory function in mice. Scientific Reports, 2016, 6, 30757.	3.3	3
383	Concordance between self-reported symptoms and clinically ascertained peripheral neuropathy among childhood cancer survivors: the St. Jude Lifetime Cohort Study. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, cebp.0644.2021.	2.5	3
384	New insights into methotrexate accumulation in leukemia cells in vivo. Molecular and Cellular Oncology, 2021, 8, 1865086.	0.7	3
385	PHASE II EVALUATION OF CISPLATIN IN CHILDREN WITH NEUROBLASTOMA AND OTHER MALIGNANT SOLID TUMORS. , 1980, , 477-484.		3
386	Modulation of the Glycolysis Pathway Reverses Prednisolone Resistance in Pediatric Acute Lymphoblastic Leukemia Cells. Blood, 2008, 112, 17-17.	1.4	3
387	6-Mercaptopurine (6MP) Intake during Maintenance for Childhood Acute Lymphoblastic Leukemia (ALL) - a Comparison of Self-Report and Electronic Monitoring: A Report from the Children's Oncology Group (COG) Study AALL03N1. Blood, 2015, 126, 82-82.	1.4	3
388	Reduced Folate Carrier Expression in Acute Lymphoblastic Leukemia: A Mechanism for Ploidy but not Lineage Differences in Methotrexate Accumulation. Blood, 1999, 93, 1643-1650.	1.4	3
389	PDE4B Modulates Glucocorticoid Sensitivity in Childhood Acute Lymphoblastic Leukemia. Blood, 2012, 120, 530-530.	1.4	3
390	Genomic Landscape of Relapsed Acute Lymphoblastic Leukemia. Blood, 2015, 126, 692-692.	1.4	3
391	Advances in pediatric pharmacokinetics and therapeutics. Journal of Pediatrics, 1990, 117, 996-1001.	1.8	2
392	An interview with a distinguished pharmaceutical scientist. William E. Evans. Pharmaceutical Research, 1999, 16, 785-789.	3.5	2
393	ACCP: From zero to forty. JACCP Journal of the American College of Clinical Pharmacy, 2020, 3, 8-9.	1.0	2
394	Improving the treatment of childhood acute lymphoblastic leukemia by optimizing the use of 70-year-old drugs. Haematologica, 2021, 106, 2794-2796.	3.5	2
395	Pegaspargase Allergic Reactions Are Related to Anti-Pegaspargase Antibodies and to Intensity of Intrathecal Therapy. Blood, 2018, 132, 2697-2697.	1.4	2
396	Genome-Wide Association Study Identifies PNPLA3 I148M Variant Associated with Elevated Transaminase Levels after Induction Therapy in Pediatric ALL Patients. Blood, 2015, 126, 3714-3714.	1.4	2

#	Article	IF	Citations
397	Factors associated with nonadherence to oral 6-mercaptopurine (6MP) in children with acute lymphoblastic leukemia (ALL): A report from Childrenâ€™s Oncology Group (COG) study AALL03N1.. Journal of Clinical Oncology, 2014, 32, 10013-10013.	1.6	2
398	Chemotherapy in the Pediatric Patient. , 2009, , 173-207.		2
399	Genome-Wide Association Study Identifies a Novel Susceptibility Locus At 10p12.31-12.2 for Childhood Acute Lymphoblastic Leukemia in Ethinically Diverse Populations. Blood, 2012, 120, 877-877.	1.4	2
400	High Incidence of Induction Failure and Poor Outcome in Patients with Gamma Delta T Cell Acute Lymphoblastic Leukemia. Blood, 2015, 126, 1421-1421.	1.4	2
401	Germline Genetic Variation in ETV6 and Predisposition to Childhood Acute Lymphoblastic Leukemia. Blood, 2015, 126, 695-695.	1.4	2
402	Simultaneous monitoring of disease and microbe dynamics through plasma DNA sequencing in pediatric patients with acute lymphoblastic leukemia. Science Advances, 2022, 8, eabj1360.	10.3	2
403	Acute Renal Failure in a Multisystem Allergic Reaction to Sulfamethoxazole. Drug Intelligence & Clinical Pharmacy, 1975, 9, 660-662.	0.4	1
404	Reaction III. Drug Intelligence & Clinical Pharmacy, 1984, 18, 331-332.	0.4	1
405	Continue to study childhood ALL. Blood, 2008, 111, 468-469.	1.4	1
406	Integrated Analysis of Pharmacokinetic, Clinical, and SNP Microarray Data Using Projection onto the Most Interesting Statistical Evidence with Adaptive Permutation Testing. , 2009, , .		1
407	2012 Remington Lecture: Culture trumps strategy: We must encourage the next generation of pharmacists to keep looking over the horizon and not be limited by what they can see today. Journal of the American Pharmacists Association: JAPhA, 2012, 52, 450-453.	1.5	1
408	Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Determinants of Osteonecrosis In Children with Acute Lymphoblastic Leukemia.. Blood, 2010, 116, 1033-1033.	1.4	1
409	Prednisolone Resistance in Pediatric Acute Lymphoblastic Leukemia Can Be Synergistically Overcome by Inhibition of Anti-Apoptotic MCL1 and Glycolysis. Blood, 2012, 120, 3528-3528.	1.4	1
410	HLA-DRB1*07:01 Is Associated With Asparaginase Allergies In Children With Acute Lymphoblastic Leukemia. Blood, 2013, 122, 60-60.	1.4	1
411	Glutamate Receptor Polymorphisms Contribute to Glucocorticoid-Associated Osteonecrosis. Blood, 2014, 124, 367-367.	1.4	1
412	Expression of an Oncogenic ERG isoform Characterizes a Distinct Subtype of B-Progenitor Acute Lymphoblastic Leukemia. Blood, 2015, 126, 693-693.	1.4	1
413	Comprehensive Functional Characterization of Germline ETV6 Variants Associated with Inherited Predisposition to Acute Lymphoblastic Leukemia in Children. Blood, 2016, 128, 1085-1085.	1.4	1
414	Global Gene Expression in Leukemic Blasts as a Function of Germline Genetic Variation.. Blood, 2004, 104, 144-144.	1.4	1

#	Article	IF	Citations
415	Genes Regulating B-Cell Development and Differentiation Are Mutated in 40% of Pediatric Acute Lymphoblastic Leukemia.. Blood, 2006, 108, 217-217.	1.4	1
416	Genetically Defined Racial Differences Underlie Risk of Relapse in Childhood Acute Lymphoblastic Leukemia. Blood, 2008, 112, 14-14.	1.4	1
417	ARID5B Genetic Polymorphisms Contribute to Racial Disparities In Childhood Acute Lymphoblastic Leukemia: A Children's Oncology Group Study. Blood, 2010, 116, 8-8.	1.4	1
418	Excellent Outcome for ETV6/RUNX1-Positive Childhood Acute Lymphoblastic Leukemia (ALL) with Contemporary Therapy. Blood, 2010, 116, 495-495.	1.4	1
419	BCR-ABL1-Like Cases In Pediatric Acute Lymphoblastic Leukemia: A Comparison Between COG/St. Jude and Dutch DCOG Signatures. Blood, 2013, 122, 2633-2633.	1.4	1
420	Drug Concentration Monitoring. Progress in Clinical Biochemistry and Medicine, 1988, , 1-16.	0.5	1
421	A Genome-Wide Association Study of Susceptibility to Acute Lymphoblastic Leukemia in Adolescents and Young Adults. Blood, 2014, 124, 132-132.	1.4	1
422	Antileukemic Efficacy of Continuous Vs Discontinuous Dexamethasone in Murine Xenografts of Acute Lymphoblastic Leukemia. Blood, 2014, 124, 3701-3701.	1.4	1
423	Pharmacokinetic, pharmacodynamic, and pharmacogenetic considerations. , 2006, , 391-413.		1
424	Clofarabine-Based Chemotherapy for KMT2Ar Infantile Acute Lymphoblastic Leukemia. Blood, 2021, 138, 3406-3406.	1.4	1
425	Gene expression microarrays as a prognostic test. Clinical Advances in Hematology and Oncology, 2005, 3, 902-4.	0.3	1
426	Chloral Hydrateâ€"Warfarin Interaction. American Journal of Health-System Pharmacy, 1975, 32, 241-243.	1.0	0
427	Unit dose radiopharmaceutical service as a component of total pharmacy practice. American Journal of Health-System Pharmacy, 1976, 33, 61-63.	1.0	0
428	Microbiological Hazards of Infusion Therapy. American Journal of Health-System Pharmacy, 1977, 34, 775-775.	1.0	0
429	Treatment of the Totally Occluded Abdominal Aorta. Vascular Surgery, 1978, 12, 287-293.	0.3	0
430	Comparison of Antibiotic Serum Concentrations After Intramuscular Oxacillin and Oral Cloxacillin in Children. American Journal of Health-System Pharmacy, 1978, 35, 1380-1382.	1.0	0
431	A Randomized-Blinded Evaluation of Analytical Error Associated with the Enzyme Immunoassay (EMITÂ®) of Gentamicin. Therapeutic Drug Monitoring, 1982, 4, 409-412.	2.0	0
432	ACCP Forms Specialty Committee. American Journal of Health-System Pharmacy, 1982, 39, 44-46.	1.0	0

#	Article	IF	Citations
433	Academic Research Fellowships in Clinical Pharmacy. Drug Intelligence & Clinical Pharmacy, 1987, 21, 106-109.	0.4	0
434	Clinical pharmacology of anticancer drugs in children. Current Opinion in Pediatrics, 1990, 2, 254-260.	2.0	0
435	Pharmacodynamics of cancer chemotherapy: childhood ALL as a model. International Congress Series, 2001, 1220, 203-222.	0.2	0
436	From the Editors: progress and the way forward. Pharmacogenetics and Genomics, 2002, 12, 273-274.	5.7	0
437	John H. Rodman, Pharm.D., FCCP January 6, 1946â€“April 29, 2006. Pharmacotherapy, 2007, 27, 1-2.	2.6	0
438	MicroRNAs MiR-520d And Let-7d Are Dysregulated In An Animal Model Of Pulmonary Arterial Hypertension: Detection By Endoarterial Biopsy. , 2010, , .		0
439	Reply to B.A. Kamen et al. Journal of Clinical Oncology, 2011, 29, 3494-3495.	1.6	0
440	Pharmacokinetic, pharmacodynamic, and pharmacogenetic considerations. , 0, , 309-331.		0
441	Germline exome variation in children with acute lymphoblastic leukemia (ALL): Preliminary Findings. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S177.	0.4	0
442	Pharmacogenomics and Hematologic Diseases. , 2018, , 79-91.		0
443	MO006INFLAMMASOME ACTIVATOR NLRP3 HYPOMETHYLATION IS ASSOCIATED WITH GLUCOCORTICOID RESISTANCE IN PATIENTS WITH IDIOPATHIC NEPHROTIC SYNDROME. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
444	Genetic Polymorphisms in the Promoter Region of the beta-2 Adrenergic Receptor Are Associated with the Early Response of Acute Lymphoblastic Leukemia to Chemotherapy.. Blood, 2004, 104, 1959-1959.	1.4	0
445	Genetic Polymorphisms and the Toxicity of Antileukemic Agents in Children with Acute Lymphoblastic Leukemia.. Blood, 2004, 104, 1964-1964.	1.4	0
446	Inosine-Triphosphate-Pyrophosphatase Genotype Is a Determinant of Severe Fever with Neutropenia Following Treatment of Acute Lymphoblastic Leukemia with Combination Chemotherapy That Includes Mercaptopurine Adjusted for Thiopurine-S-Methyltransferase Genotype.. Blood, 2007, 110, 2827-2827.	1.4	0
447	Pharmacogenomics of childhood acute lymphoblastic leukemia (ALL). Journal of Clinical Oncology, 2009, 27, s3-s3.	1.6	0
448	Genetic Variations in GRIA1 On Chromosome 5q33 Related to Asparaginase Hypersensitivity in Childhood Acute Lymphoblastic Leukemia (ALL).. Blood, 2009, 114, 112-112.	1.4	0
449	Improved Prognosis for Older Adolescents with Acute Lymphoblastic Leukemia. Blood, 2010, 116, 498-498.	1.4	0
450	SLCO1B1 Variation and Methotrexate Disposition in Children with Acute Lymphoblastic Leukemia: The Importance of Rare Variants in Pharmacogenetics. Blood, 2011, 118, 571-571.	1.4	0

#	Article	IF	Citations
451	Systemic Exposure to Dexamethasone and Asparaginase Affects Risk of Relapse in Children with Acute Lymphoblastic Leukemia. Blood, 2011, 118, 2550-2550.	1.4	0
452	Discovery of Novel Recurrent Mutations in Childhood Early T-Cell Precursor Acute Lymphoblastic Leukemia by Whole Genome Sequencing - a Report From the St Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project. Blood, 2011, 118, 68-68.	1.4	0
453	Aurora Kinases in Childhood Acute Leukemia: The Promise of Aurora Kinase B As Drugable Target. Blood, 2011, 118, 1476-1476.	1.4	0
454	Genome-Wide Association Study Identifies Germline Polymorphisms Associated with Relapse of Childhood Acute Lymphoblastic Leukemia. Blood, 2012, 120, 878-878.	1.4	0
455	The Potential of Aurora Kinases A and B As Therapeutic Targets in Pediatric Acute Leukemia. Blood, 2012, 120, 1465-1465.	1.4	0
456	Host Thiopurine Methyltransferase Status Affects Mercaptopurine Antileukemic Effectiveness. Blood, 2012, 120, 3560-3560.	1.4	0
457	Clinical pharmacology of anticancer drugs in children: differences and similarities between children and adults. , 1987, , 29-71.		0
458	Targeted Drug Therapy in Childhood Acute Lymphoblastic Leukemia. Hamatologie Und Bluttransfusion, 1996, , 62-66.	0.0	0
459	Abstract CT409: Dexamethasone (dex) and asparaginase increase triglycerides during acute lymphoblastic leukemia (ALL) therapy in children. , 2014, , .		0
460	A Murine Model of Asparaginase Allergy. Blood, 2014, 124, 2295-2295.	1.4	0
461	Tolerability of 6-Mercaptopurine (6MP) in Patients with Thiopurine Methyltransferase (TPMT) Heterozygosity in the Context of Multi-Agent Therapy for Acute Lymphoblastic Leukemia (ALL). Blood, 2014, 124, 3722-3722.	1.4	0
462	Impact of 6 Mercaptopurine (6MP) Pill-Taking Habits on Adherence, Thioguanine Nucleotide (TGN) Levels and Relapse Risk in Children with Acute Lymphoblastic Leukemia (ALL): Results from a Childrenâ€™s Oncology Group (COG) Study (AALL03N1). Blood, 2014, 124, 369-369.	1.4	0
463	Body Mass Index Is Not Associated with Early Treatment Response or Clinical Outcome in Children with Acute Lymphoblastic Leukemia. Blood, 2015, 126, 1299-1299.	1.4	0
464	Asparaginase May Affect Mercaptopurine Tolerability in the Context of Multi-Agent Therapy for Acute Lymphoblastic Leukemia. Blood, 2016, 128, 179-179.	1.4	0
465	Measuring mercaptopurine (6MP) adherence using red cell 6MP metabolite levels in children with acute lymphoblastic leukemia (ALL): A COG AALL03N1 study.. Journal of Clinical Oncology, 2017, 35, 10514-10514.	1.6	0
466	Germline Genetic IKZF1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia. SSRN Electronic Journal, 0, , .	0.4	0
467	The Effect of Asparaginase on Serum Triglycerides during Therapy for Acute Lymphoblastic Leukemia. Blood, 2018, 132, 2665-2665.	1.4	0
468	The Impact of Genetic Ancestry on the Biology and Prognosis of Childhood Acute Lymphoblastic Leukemia. Blood, 2021, 138, 3476-3476.	1.4	0

#	Article	IF	Citations
469	Creating an infrastructure for pediatric oncology drug development. Clinical Advances in Hematology and Oncology, 2007, 5, 198-200.	0.3	0
470	CASPorter: A Novel Inducible Human CASP1/NALP3/ASC Inflammasome Biosensor. Journal of Inflammation Research, 2022, Volume 15, 1183-1194.	3.5	0
471	Remembering Donald Pinkel, MD: Acute lymphoblastic leukaemia pioneer September 7, 1926 â€“March 9, 2022. Leukemia, 2022, 36, 1444-1445.	7.2	0